Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: A case series

Clinical Infectious Diseases

Volumn 39, Issue 8, 2004, Pages 1214-1222

  Jacobson, Michael C ^a   Dezube, Bruce J ^c   Aboulafia, David M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; HOMOCYSTEINE; LIPID; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; WARFARIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CANCER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LABORATORY TEST; LIPID BLOOD LEVEL; LUNG EMBOLISM; LYMPHOCYTE COUNT; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; THROMBOPHILIA; VEIN THROMBOSIS; VIRUS CLASSIFICATION; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; ANTICOAGULANTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM; VIRAL LOAD; WARFARIN;

EID: 12844277984     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/424664     Document Type: Article

References (37)

1. Copur AS, Smith PR, Gomez V, Bergman M, Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS 2002; 16:205-9.
2. Saber AA, Aboolian A, LaRaja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg 2001; 67:645-7.
3. Wilkes MS, Fortwin AH, Felix JC, Godwin TA, Thompson WG. Value of necropsy in acquired immunodeficiency syndrome. Lancet 1988; 2: 85-8.
4. Afessa B, Green W, Chiao J, Frederick W. Pulmonary complications of HIV infection. Chest 1998; 113:1225-9.
5. Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15:311-20.
6. Karpatkin S, Nardi M, Green D. Platelet and coagulation defects associated with HIV-1 infection. Thromb Haemost 2002; 88:389-401.
7. Lafon ME, Steffan AM, Royer C, et al. HIV-1 infection induces functional alterations in human liver endothelial cells in primary culture. AIDS 1994; 8:747-52.
8. Trotti R, Rondanelli M, Anesi A, Gabanti E, Brustia R, Minoli L. Increased erythrocyte glutathione peroxidase activity and serum tumor necrosis factor-α in HIV-infected patients: relationship to on-going prothrombotic state. J Hematother Stem Cell Res 2002; 11:369-75.
9. Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci U S A 2001; 98:10142-7.
10. Abuaf N, Laperche S, Rajoely B, et al. Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb Haemost 1997; 77:856-61.
11. Feffer SE, Fox FL, Orsen MM, Harjai KJ, Glatt AE. Thrombotic tendencies and correlation with clinical status in patients infected with HIV. South Med J 1995; 88:1126-30.
12. Berruyer M, Causse X, Dechavanne M, Trepo C. Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1992; 5:484-9.
13. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Swiss HIV Cohort Study. Circulation 1999; 100:700-5.
14. Wolf K, Tsakiris DA, Weber R, et al. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185: 456-62.
15. Kuritzkes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. N Engl J Med 2003; 348:679-80.
16. Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86:939-43.
17. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29:441-9.
18. Vayá A, Mira Y, Ferrando F, et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002; 118:255-9.
19. Centers for Disease Control and Prevention. Third National Health and Nutrition Examination Survey (NHANES III), 1983-1994. 2004. Available at: http://www.cdc.gov/nchs/nhanes.htm. Accessed 22 June 2004.
20. George SL, Swindells S, Knudson R, Stapleton JT. Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. Am J Med 1999; 107:624-6.
21. Capron L, Kim Y, Laurian C, et al. Atheroembolism in HIV-positive individuals. Lancet 1992; 340:1039-40.
22. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328.
23. Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000; 14:321-4.
24. Laing RBS, Breetle RP, Leen CLS. Venous thrombosis in HIV infection. Int J STD AIDS 1996; 7:82-5.
25. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997; 78:1-6.
26. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86:452-63.
27. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31:256-63.
28. de Larranaga GF, Forastiero RR, Carreras LO, Alonso BS. Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome. Thromb Res 1999; 96:19-25.
29. Abuaf N, Laperche S, Rajoely B, et al. Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb Haemost 1997; 77:856-61.
30. Toulon P, Gris JC, Salmon D, et al. Antiphospholipid antibodies in HIV-infected patients are not associated with a prothrombotic state. Nouv Rev Fr Hematol 1995; 37(Suppl 2):S97-101.
31. Ramos-Casals M, Cervera R, Lagrotta M, et al. Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. Hispanoamerican Study Group of Autoimmune Manifestations of Chronic Viral Diseases (HISPAMEC). Clin Infect Dis 2004; 38:1009-16.
32. Kaufmann T, Nisce LZ, Metroka C. Thromboembolism in AIDS-related Kaposi's sarcoma. JAMA 1991; 266:2834.
33. Prandoni P, Bilora F, Marchiora A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348:1435-41.
34. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesterol ester accumulation in macrophages. J Clin Invest 2003; 111:389-97.
35. Hui DY. HIV protease inhibitors and atherosclerosis. J Clin Invest 2003; 111:317-8.
36. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-10.
37. Witz M, Lehman J, Korzets Z. Acute brachial artery thrombosis as the initial manifestation of human immunodeficiency virus infection. Am J Hematol 2000; 64:137-9.